Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
<h4>Background</h4>Gemcitabine and pemetrexed have been used as maintenance therapy. However, few systematic reviews and meta-analyses have assessed their effects in the newest studies. This systematic review and meta-analysis were conducted to assess the role of gemcitabine and pemetrex...
Saved in:
| Main Authors: | Xingsheng Hu, Ke Pu, Xuqin Feng, Shimin Wen, Xi Fu, Cuihua Guo, Wenwu He |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0149247&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Experience of pemetrexed in maintenance therapy for metastatic lung adenocarcinoma
by: L. Yu. Vladimirova, et al.
Published: (2021-03-01) -
Acute pancreatitis caused by pemetrexed, carboplatin, and gemcitabine in a patient with lung cancer: A rare case report
by: Vishal Kulkarni, et al.
Published: (2019-01-01) -
Real-world analysis of survival outcomes in advanced EGFR-mutant NSCLC patients treated with platinum-pemetrexed after EGFR-TKI treatment failure
by: Zong-Han Yao, et al.
Published: (2025-08-01) -
High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy
by: Shugui Wu, et al.
Published: (2025-05-01) -
Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%
by: Yoshihito Kogure, MD, PhD, et al.
Published: (2025-03-01)